Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e fold » _ fold (Expand Search), 5 fold (Expand Search), 2 fold (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e fold » _ fold (Expand Search), 5 fold (Expand Search), 2 fold (Expand Search)
-
1561
-
1562
-
1563
Decreased self-renewal capacity associated with senescence was prevented in human MSCs following treatment with Ki16425, an LPA<sub>1</sub>/LPA<sub>3</sub> antagonist.
Published 2012“…Human MSCs at passage 2 were cultured in the presence or absence of Ki16425 for the indicated days prior to cell lysis. Fold-change represents decrease in band intensity of Ki16425 treatment for 18 days compared with a control treatment for the same period of time. …”
-
1564
-
1565
-
1566
-
1567
-
1568
-
1569
-
1570
-
1571
-
1572
-
1573
-
1574
-
1575
Modafinil treatment prevents METH-induced decrease in DAT immunoreactivity in the striatum.
Published 2013“…Average integrated density (% control) was determined in a region of interest in the dorsolateral striatum in mice (n = 5−8 sacrificed 48 hours (I) or 6 days (J) after the last METH injection. …”
-
1576
-
1577
-
1578
-
1579
MVEC microvessel formation is restricted in hydrogels exhibiting increased stiffness or decreased concentration of adhesive peptides.
Published 2020“…An unpaired student’s t-test detect statistical significance, *p<0.05 for 7.5 wt% hydrogels containing 3 mM RGD relative to either (<b>A, C-F</b>) 15wt% hydrogels containing 3 mM RGD or (<b>G, I-L</b>) 7.5wt% hydrogels containing 1 mM RGD.…”
-
1580
Ophthalmic administration of CXCR3 antagonist decreases intraocular pressure in a rat model of ocular hypertension.
Published 2012“…<p><i>(A)</i> A single administration of CXCR3 antagonist (NBI-74330, 1 µM, 100 µL) induces a transient decrease in intraocular pressure (n = 10 in each group). …”